CopyMark Law Group
4.9/5
Drawing for VOLITION

USPTO serial 98208918

VOLITION

Reviewed by CopyMark Law Group

Status 700
Filing date
Status date
Registration date
Sep 8, 2026
Examiner
INNES, ISABEL J
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with VOLITION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Amanda G. Hyland

Amanda G. Hyland Buchalter LLP3475 Piedmont Road NESTE 1100Atlanta, GA 30305

Goods and services

ClassDescriptionStatusFirst use
001Chemicals and biological preparations used in industry and science; chemical and biological reagents for use in industry and science; diagnostic reagents for scientific and research purposes; chemical and biological preparations and reagents for use in diagnostic and analytical tests, including in vitro diagnostic laboratory tests, for scientific purposes and not for medical or veterinary purposes; Reagents for scientific use in the field of life sciences; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); assays for testing stem cell differentiation status, other than for medical or veterinary useACTIVEJan 20, 2021
005Pharmaceutical, chemical, biological, medical preparations for treating diseases caused by epigenetic and nucleosomal changes, namely, cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); biological tissue cultures for medical, therapeutic and veterinary purposes for use in the fields of epigenetics and nucleosomes; chemical and biological reagents for medical, therapeutic and veterinary purposes for use in the fields of epigenetics and nucleosomes; Diagnostic reagents, preparations and substances for medical use in the field of epigenetics and nucleosomes; diagnostic reagents for medical and veterinary use; Diagnostic reagents for medical use for in vitro diagnosis; Diagnostic preparations for medical purposes for detection, monitoring and diagnosis of cancer, sepsis, Covid-19, infection, dementia, Alzheimer's disease, thrombosis, vascular damage and inflammation, autoimmune diseases, and disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Pharmaceutical preparations for the treatment of conditions related to in vivo and ex vivo organ and tissue transplant; Medical diagnostic assays for stem cell differentiation status; blood for medical and veterinary purposes; blood plasma; cultures of microorganisms for medical and veterinary use; diagnostic biomarker reagents for medical and veterinary purposes; Transplants, namely, living human allograft tissueACTIVEJan 20, 2021
010Medical and therapeutic apparatus and instruments for use in treatment of cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS) in humans and animals; Medical and veterinary devices for diagnosing cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs) pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnostic apparatus for analyzing and measuring cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); medical apparatus, instruments and equipment for use in the diagnosis, monitoring and treatment of cancer; medical apparatus, instruments and equipment for use in the monitoring and diagnosis of sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage and inflammation, disorders associated with neutrophil extracellular traps (NETs) and pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); medical apparatus, instruments and equipment for use in monitoring the immune system, namely, for monitoring blood properties; Medical diagnostic apparatus for testing for cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnostic apparatus for use with chemical and biological reagents, for testing for cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical apparatus for use in carrying out diagnostic assays; Medical apparatus, equipment and instruments for monitoring diseases namely, cancer sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); apparatus for DNA and RNA testing for medical purposes; Medical apparatus for use in regeneration of transplant tissues and organs; blood testing apparatus; dialyzers; apheresis devices for medical use; structural parts for all the aforesaid goodsACTIVEJan 20, 2021
042Scientific and technological services, namely, custom design of chemical reagents and biological assays and research, all in the field of epigenetics and nucleosomes; Industrial research and scientific analysis in the field of epigenetics and nucleosomes; research and development services in the field of biotechnology, medical technology, assays, medical diagnostics, diagnostic reagents, substances, preparations and materials, detection of cancer and other diseases; scientific consulting in the field of research and development of biotechnology, medical technology, assays, medical diagnostic reagents, and technology for detecting cancer and other diseases; Providing analytical reagent sample testing and diagnostics services for others for scientific research purposes in the field of epigenetics and nucleosomes; Product design and development in the field of medical diagnostic testing apparatus and reagents; Blood analysis services for scientific research purposes; Veterinary research laboratory services; DNA and RNA analysis services for scientific research purposes in the field of cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant health, thrombosis, vascular damage, inflammation, disorders associated with the immune system and disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS)ACTIVEFeb 11, 2022
044Medical services and veterinary services; diagnostic medical testing and treatment of disorders, namely, cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, and disorders associated with neutrophil extracellular traps (NETs); medical analysis services relating to the treatment of persons and animals; health care; hospital services; Veterinary services, namely, advisory of medical, diagnostic or surgical services for animals; human tissue bank services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical clinic services; medical screening; medical equipment rental; epigenetic testing for medical purposes, namely, for diagnosing disease, monitoring disease and treatment efficacy; medical analysis for the diagnosis and treatment of persons and animals; Medical and health care services in the field of DNA, genetics and genetic testing; genetic testing of animals for diagnostic or treatment purposes; DNA and RNA analysis services for medical purposes in the field of cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnosis and prognosis in the field of diseases related to epigenetic and nucleosomal changes, namely cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); genetic testing for medical purposes; Blood analysis services for diagnostic purposes provided by medical laboratories; Veterinary analysis services for diagnostic and treatment purposes provided by veterinary laboratoriesACTIVEFeb 11, 2022

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 8, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Sep 8, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 18, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Aug 18, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Aug 4, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jun 9, 2026IUAFUSE AMENDMENT FILED—
Jun 9, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Dec 9, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 14, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 14, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 8, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 15, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 15, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Sep 15, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 15, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 15, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 11, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 11, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 11, 2025ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 19, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 19, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 19, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 15, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 15, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 15, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 7, 2025XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Apr 7, 2025XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jan 7, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 7, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 7, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 7, 2025ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Nov 18, 2024PBSRWITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST—
Oct 17, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 11, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 11, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 11, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 25, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 25, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 25, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 23, 2024DOCKASSIGNED TO EXAMINER—
Oct 13, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 7, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance